NovaBay Pharmaceuticals: Investor and Contact Information
Table of Contents
This page provides key information for investors and those seeking to connect with NovaBay Pharmaceuticals, including contact details for their Chief Financial Officer and links to their social media presence.
Company Overview
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for addressing significant unmet medical needs. Their lead product, Avenova, is an FDA-cleared antimicrobial lid and lash cleanser for the management of Demodex blepharitis.NovaBay is also developing therapies for other indications, leveraging its patented A20 technology. Learn more about NovaBay’s pipeline and technology.
NovaBay Contact Information
For investor inquiries and other communications, please contact:
Tommy Law
Chief Financial Officer
tlaw@novabay.com
Stay Connected
Keep up-to-date with NovaBay’s progress through the following channels:
- Facebook: Like NovaBay on Facebook
- LinkedIn: Connect with NovaBay on LinkedIn
- Website: Visit NovaBay’s Website
Recent Developments
As of October 21, 2025, NovaBay continues to advance its clinical programs and expand the commercialization of Avenova.Check the Investor Relations section of the NovaBay website for the latest press releases and updates.
Key Takeaways
- NovaBay Pharmaceuticals is a biotechnology company focused on innovative therapies.
- Tommy Law serves as the Chief Financial officer and primary investor contact.
- Investors can stay informed through NovaBay’s website, Facebook, and LinkedIn.
Disclaimer: This information is current as of October 21, 2025, and is based on publicly available information. Investors are encouraged to consult novabay’s official filings with the Securities and Exchange Commission (SEC) for the most accurate and up-to-date information. Search SEC filings here.